At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.
One example of the impactful ways we advance our mission to cure follicular lymphoma (FL) is through our seed funding of the world-renowned Dana-Farber Cancer Institute.
In recent weeks there have been a number of announcements regarding an alternative treatment option now being available for adults with relapsed/ refractory indolent follicular lymphoma (FL) across the EU and transformed follicular lymphoma within the UK.
The Follicular Lymphoma Foundation (FLF) was thrilled to participate in the recent American Society of Hematology (ASH) Annual Meeting.
FLF’s CMO highlights key takeaways from ASH 2024 on follicular lymphoma, from immunotherapy to new treatments.
Plain English Summary of the Publication:
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemo-immunotherapy.
Professor Jessica Okosun, FLF Scientific Advisor, answers your questions on chemotherapy-free options
Global patient survey results reveal key insights into patient perspectives on immunotherapy and information preferences
We are pleased to announce the publication of our latest update, “Follicular Lymphoma: Mid-year Update on Pathways for Clinical and Translational Investigations.
View our webinar focused on sharing experiences and improving understanding of clinical trials.
The team updates from recent scientific conferences on the latest research in follicular lymphoma, from cutting-edge therapies to genetic insights.
Minimal/measurable residual disease refers to the small number of cancer cells remaining in the body after treatment.
How do we improve immunotherapy treatments to ensure long-lasting effectiveness, fewer side effects, and ensure they are accessible?
Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.
Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.
This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.
At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.
Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular
ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25
The FLF’s Precision Medicine Programme Research Goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in
Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has
Interesting summary of the impact and effectiveness of antibody responses to SARS- CoV-2 vaccines in patients with hematologic malignancies. A project from Michael J. Garil
For many people living with Follicular Lymphoma, periodic blood tests become a regular feature. There are several reasons you might need blood tests when affected
Any potential treatments for Follicular Lymphoma (and other forms of Non-Hodgkin lymphoma) must undergo extensive testing. They must be fully researched to confirm that they
The FLF places the patient at the heart of our organisation. This survey collated the unmet needs and prioritised our research goals.
